Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 2,728 Cr.
- Current Price ₹ 445
- High / Low ₹ 648 / 292
- Stock P/E
- Book Value ₹ 46.5
- Dividend Yield 0.00 %
- ROCE -3.39 %
- ROE -9.97 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 9.67 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -4.39% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 679 | 647 | 530 | 184 | 96 | 158 | 344 | 236 | 257 | 360 | 310 | 413 | |
| 612 | 534 | 460 | 192 | 243 | 248 | 343 | 308 | 320 | 345 | 317 | 431 | |
| Operating Profit | 68 | 113 | 70 | -8 | -147 | -90 | 0 | -73 | -63 | 14 | -7 | -18 |
| OPM % | 10% | 17% | 13% | -4% | -152% | -57% | 0% | -31% | -24% | 4% | -2% | -4% |
| 28 | 75 | 16 | 84 | 322 | -14 | 21 | 13 | 34 | 25 | 17 | 18 | |
| Interest | 93 | 115 | 104 | 103 | 105 | 5 | 8 | 7 | 10 | 14 | 15 | 25 |
| Depreciation | 66 | 71 | 66 | 34 | 33 | 27 | 27 | 26 | 24 | 21 | 20 | 19 |
| Profit before tax | -63 | 1 | -84 | -61 | 37 | -136 | -13 | -94 | -63 | 4 | -26 | -44 |
| Tax % | 3% | 38% | -14% | 17% | 29% | 13% | 12% | 0% | 40% | 16% | -42% | -32% |
| -65 | 1 | -73 | -72 | 27 | -153 | -14 | -94 | -88 | 4 | -15 | -30 | |
| EPS in Rs | -10.64 | 0.14 | -11.85 | -11.73 | 4.33 | -24.97 | -2.36 | -15.27 | -14.28 | 0.58 | -2.48 | -4.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | 17% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -21% |
| 3 Years: | 19% |
| TTM: | -95% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 5% |
| 3 Years: | 54% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | -17% |
| 5 Years: | -13% |
| 3 Years: | -4% |
| Last Year: | -10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 517 | 518 | 450 | 382 | 412 | 887 | 502 | 409 | 320 | 323 | 308 | 279 |
| 1,031 | 1,035 | 1,023 | 970 | 689 | 67 | 65 | 84 | 102 | 125 | 228 | 265 | |
| 325 | 248 | 303 | 316 | 335 | 179 | 217 | 263 | 296 | 300 | 327 | 302 | |
| Total Liabilities | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 852 |
| 1,060 | 988 | 942 | 891 | 496 | 499 | 464 | 454 | 435 | 423 | 416 | 457 | |
| CWIP | 17 | 19 | 28 | 37 | 3 | 4 | 13 | 1 | 28 | 97 | 119 | 91 |
| Investments | 395 | 395 | 345 | 345 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| 408 | 406 | 467 | 401 | 940 | 633 | 313 | 307 | 260 | 234 | 334 | 303 | |
| Total Assets | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 852 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45 | 98 | 104 | 172 | 107 | -83 | 38 | -53 | -11 | 33 | 4 | 0 | |
| -29 | 23 | -18 | -3 | -10 | -17 | -37 | 40 | 2 | -47 | -61 | 0 | |
| -11 | -129 | -91 | -164 | -98 | 109 | -7 | 10 | 9 | 13 | 90 | 0 | |
| Net Cash Flow | 5 | -8 | -5 | 6 | -2 | 10 | -6 | -3 | 1 | -1 | 33 | 0 |
| Free Cash Flow | 41 | 97 | 80 | 157 | 102 | -69 | 28 | -59 | -10 | -36 | -49 | 0 |
| CFO/OP | 71% | 69% | 140% | -2,130% | -73% | 83% | 8,010% | 71% | 15% | 247% | -73% | 0% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 80 | 121 | 283 | 96 | 41 | 37 | 36 | 17 | 11 | 25 | 27 |
| Inventory Days | 178 | 233 | 304 | 618 | 203 | 619 | 180 | 421 | 260 | 278 | 541 | 218 |
| Days Payable | 236 | 295 | 490 | 1,002 | 373 | 847 | 257 | 472 | 289 | 299 | 586 | 231 |
| Cash Conversion Cycle | -4 | 17 | -65 | -102 | -74 | -188 | -39 | -15 | -12 | -10 | -21 | 15 |
| Working Capital Days | -229 | -80 | -133 | -682 | -49 | 892 | 4 | -63 | -135 | -79 | -141 | -8 |
| ROCE % | 2% | 4% | 4% | 3% | -14% | -8% | -1% | -16% | -13% | 4% | -2% | -3% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Countries Exported to (Pharmaceutical Formulations) count |
|
|||||||||
| Countries where Vaccines are Registered count |
||||||||||
| Electricity Consumption per Unit (Vaccines) kWh per 1000 doses |
||||||||||
| Patents Granted Globally count |
||||||||||
| Pediatricians Covered count |
||||||||||
| Total Distributors (Pharma + Vaccines) count |
||||||||||
| Vaccine Production Volume thousand doses |
||||||||||
| Vaccine Segment Revenue Share % |
||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Updates In Relation To Receipt Of Four Awards Dated March 19, 2026 From The Presiding Officer (In The Rank Of Additional District Judge) Of Industrial Tribunal, S.A.S. Nagar, Mohali
16 Jul - Filed appeal on July 16, 2026 against fourth tribunal award; High Court granted interim no-coercive-order relief.
- Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011 13 Jul
-
Updates In Relation To Receipt Of Four Awards Dated March 19, 2026 From The Presiding Officer (In The Rank Of Additional District Judge) Of Industrial Tribunal, S.A.S. Nagar, Mohali
7 Jul - Panacea Biotec appealed three of four industrial tribunal awards on July 6, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jul - Please find attached certificate dated July 01, 2026, issued by Skyline Financial Services Pvt. Ltd. , RTA under Regulation 74(5) of the SEBI (Depositories and …
-
Demat Status Report For The Month Of June 2026
7 Jul - No share has been dematerialised during June 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. ....
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix